Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The oxidized glutathione mimetic NOV-002 is a unique anti-tumor agent that not only has the ability to inhibit tumor cell… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
NOV-002 is a glutathione disulfide (GSSG) mimetic that is the subject of clinical investigation in oncology indications. GSSG is… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2010
2010
NOV-002 is a glutathione disulfide (GSSG) mimetic with chemoprotective activity. Previous and ongoing clinical studies… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2010
2010
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance… Expand
Is this relevant?
2008
2008
NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
NOV-002 is a novel therapeutic agent in development for oncology indications used in combination with chemotherapy. Clinical… Expand
Is this relevant?
2006
2006
17021 Background: NOV-002 is a proprietary formulation of oxidized glutathione that modulates production of cytokines and… Expand
Is this relevant?
Review
2005
Review
2005
Anticancer drug development using the platform of glutathione (GSH), glutathione S-transferases (GST) and pathways that maintain… Expand
Is this relevant?